{'52WeekChange': None,
 'SandP52WeekChange': None,
 'address1': '2525 West End Avenue',
 'address2': 'Suite 950',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 3.35,
 'askSize': 1100,
 'averageDailyVolume10Day': 112712,
 'averageVolume': 52806,
 'averageVolume10days': 112712,
 'beta': 0.409523,
 'beta3Year': None,
 'bid': 3.2,
 'bidSize': 1000,
 'bookValue': 3.257,
 'category': None,
 'circulatingSupply': None,
 'city': 'Nashville',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 3.29,
 'dayLow': 3.23,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': 132.302,
 'enterpriseToRevenue': 0.94,
 'enterpriseValue': 44310356,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '615-255-0094',
 'fiftyDayAverage': 3.304,
 'fiftyTwoWeekHigh': 6.27,
 'fiftyTwoWeekLow': 3.1,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 7833630,
 'forwardEps': 0.28,
 'forwardPE': 11.607142,
 'fromCurrency': None,
 'fullTimeEmployees': 94,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.42731,
 'heldPercentInstitutions': 0.29492,
 'industry': 'Drug Manufacturers—Specialty & Generic',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1183680000,
 'lastSplitFactor': '2:1',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/cumberlandpharma.com',
 'longBusinessSummary': 'Cumberland Pharmaceuticals Inc., a specialty '
                        'pharmaceutical company, focuses on the acquisition, '
                        'development, and commercialization of prescription '
                        'products for hospital acute care, gastroenterology, '
                        'and oncology markets in the United States and '
                        'internationally. It offers Acetadote, an injection '
                        'for the treatment of acetaminophen poisoning; '
                        'Caldolor, an injection for the treatment of pain and '
                        'fever; Kristalose, a prescription laxative, for the '
                        'treatment of chronic and acute constipation; '
                        'Omeclamox-Pak for the treatment of Helicobacter '
                        'pylori infection and duodenal ulcer disease; Vaprisol '
                        'injection for treating hyponatremia; Ethyol injection '
                        'for the reduction of xerostomia; Totect injection, '
                        'for emergency oncology intervention, to treat the '
                        'toxic effects of anthracycline chemotherapy; and '
                        'Vibativ injection, for the treatment of certain '
                        "serious bacterial infections. The company's Phase II "
                        'product candidates includes Hepatoren injection for '
                        'the treatment of critically ill patients suffering '
                        'from liver and kidney failure; Boxaban oral capsules '
                        'for the treatment of asthma patients; Vasculan oral '
                        'capsule for the treatment of systemic sclerosis; and '
                        'Portaban for the treatment of portal hypertension. It '
                        'also develops RediTrex injection for the treatment of '
                        'active rheumatoid, juvenile idiopathic, and severe '
                        'psoriatic arthritis, as well as severe disabling '
                        'psoriasis. The company markets and sells its products '
                        'through sales representatives and district managers. '
                        'Cumberland Pharmaceuticals Inc. has a strategic '
                        'alliance with Clinigen Group plc and Nordic Group '
                        'B.V. The company was incorporated in 1999 and is '
                        'headquartered in Nashville, Tennessee.',
 'longName': 'Cumberland Pharmaceuticals Inc.',
 'market': 'us_market',
 'marketCap': 49499776,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_25240322',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -4190638,
 'nextFiscalYearEnd': 1640908800,
 'open': 3.23,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.78,
 'phone': '615-255-0068',
 'previousClose': 3.29,
 'priceHint': 4,
 'priceToBook': 0.9978508,
 'priceToSalesTrailing12Months': 1.0501812,
 'profitMargins': -0.09588,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 3.29,
 'regularMarketDayLow': 3.23,
 'regularMarketOpen': 3.23,
 'regularMarketPreviousClose': 3.29,
 'regularMarketPrice': 3.23,
 'regularMarketVolume': 12209,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 15230700,
 'sharesPercentSharesOut': 0.0053,
 'sharesShort': 80732,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 87416,
 'shortName': 'Cumberland Pharmaceuticals Inc.',
 'shortPercentOfFloat': 0.0086,
 'shortRatio': 2.17,
 'startDate': None,
 'state': 'TN',
 'strikePrice': None,
 'symbol': 'CPIX',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.295,
 'twoHundredDayAverage': 3.9283452,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'fbb0fe28-9752-3ce1-bfca-efe25634b947',
 'volume': 12209,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.cumberlandpharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '37203'}